Disruptive innovations: New anti-infectives in the age of resistance

Current Opinion in Pharmacology

Volumn 13, Issue 5, 2013, Pages 673-677

  Tegos, George P ^a,b,c,d   Hamblin, Michael R ^c,d,e  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CYCLODEXTRIN DERIVATIVE; ECHINOCANDIN; GALLIUM; GALLIUM CITRATE; MICROBICIDE; NATURAL PRODUCT; PHOTOSENSITIZING AGENT; PYRROLE DERIVATIVE; SULFANILAMIDE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; BIOFILM; DROSOPHILA MELANOGASTER; DRUG SCREENING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH THROUGHPUT SCREENING; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUORUM SENSING; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; INVENTIONS; QUORUM SENSING;

EID: 84892983878     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.08.012     Document Type: Editorial

References (12)

1. Demain A, Spizek J:: The antibiotic crisis. In Antimicrobial Drug Discovery: Emerging Strategies. Edited by Tegos GP, Mylonakis E. CABI PUBLISHING; 2012.
2. Salcido RS: Super bugs: survival of the fittest. Adv Skin Wound Care 2010, 23:439.
3. Canton R, Bryan J: Global antimicrobial resistance: from surveillance to stewardship, Part 1: surveillance and risk factors for resistance. Expert Rev Anti Infect Ther 2012, 10: 1269-1271.
4. Pendleton JN, Gorman SP, Gilmore BF: Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 2013, 11: 297-308.
5. Owens RC Jr: Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn Microbiol Infect Dis 2008, 61: 110-128. (Pubitemid 351509755)
6. Yoshikawa TT: Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc 2002, 50:S226-S229. (Pubitemid 34811965)
7. Lewis K: Platforms for antibiotic discovery. Nat Rev Drug Discov 2013, 12: 371-387.
8. Lima TB, Pinto MF, Ribeiro SM, de Lima LA, Viana JC, Gomes Junior N, Candido Ede S, Dias SC, Franco OL: Bacterial resistance mechanism: what proteomics can elucidate. FASEB J 2013, 27: 1291-1303.
9. Kourtesi C, Ball AR, Huang YY, Jachak SM, Vera DM, Khondkar P, Gibbons S, Hamblin MR, Tegos GP: Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J 2013, 7: 34-52.
10. Dawson CC, Intapa C, Jabra-Rizk MA: "Persisters": survival at the cellular level. PLoS Pathog 2011, 7:e1002121.
11. Newman DJ, Cragg GM: Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012, 75: 311-335.
12. Bhardwaj AK, Vinothkumar K, Rajpara N: Bacterial quorum sensing inhibitors: attractive alternatives for control of infectious pathogens showing multiple drug resistance. Recent Pat Antiinfect Drug Discov 2013, 8: 68-83.